CD Formulation Launches GalNAc Coupling Modification Services for the Development of Drug Delivery Systems

Over the past decade, the CD Formulation’s expert team has made tireless efforts in the research and development of drug delivery systems, trying to improve the pharmacokinetics and pharmacodynamics of drugs. In order to achieve the optimal therapeutic effect, the required dose must be delivered at the target site at the appropriate time and rate. “We have developed various drug delivery technologies, including Microneedle Technology, Oral Thin Films Technology, Microencapsulation Technology, Nanoparticle Development, Microparticle Depots Design, Microsphere Technology, Multiparticulate System Formulation, and GalNAc Technology, to improve the therapeutic effect and minimize possible adverse effects at the same time,” said one of the senior scientists from CD Formulation. “And we found that GalNAc delivery is quite advantageous in terms of subcutaneous administration, duration of action, specificity of hepatic targeting, and toxicity.” As for now, CD Formulation is capable of providing customers with proven GalNAc delivery molecule synthesis and custom synthesis services for various modified GalNAc molecules, as well as a one-stop service for GalNAc-siRNA splice synthesis. Coupling GalNAc to small nucleic acid molecules can help to target binding to hepatocytes. After that, the GalNAc nucleic acid couples are taken up by hepatocytes under endocytosis, thus achieving a high degree of liver-targeted specificity for delivery. In addition, GalNAc modification also contributes to the lower occurrence of off-target tissues for drugs. With extensive experience in GalNAc coupling modification, CD Formulation now offers two major custom GalNAc molecular modification services, i.e., GalNAc-antisense nucleic acid (ASO) and GalNAc-siRNA. Please visit the website https://www.formulationbio.com/ to explore more of CD Formulation’s CRO capabilities.